Wollenberg A, et al. - Researchers tested tralokinumab as a treatment option for adults with moderate to severe atopic dermatitis (AD), with a focus on its efficacy and safety. They assessed change from baseline in Eczema Area Severity Index (EASI) and percentage of participants with an Investigator’s Global Assessment (IGA) response (0/1 score and reduction of two grades or more from baseline) at week 12 in this phase 2b study wherein adults with AD were randomized 1:1:1:1 to receive subcutaneous tralokinumab 45 mg, 150 mg, or 300 mg, or placebo, every 2 weeks for 12 weeks, with concomitant topical glucocorticoids. Findings demonstrated an acceptable safety and tolerability profile shown by tralokinumab. Early and sustained improvements in AD symptoms were observed in association with tralokinumab treatment; these findings offered evidence for targeting IL-13 in AD as tralokinumab potently and specifically neutralizes IL-13, which has an important role in AD pathogenesis.